Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer

Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma

(2021) Tuo Zhang et al.   Translational Lung Cancer Research

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis

(2020) Xiaotian Zhang et al.   BLOOD

Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy

(2020) Maria Mrakovcic et al.   Cancers

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma

(2020) Xiaoguang Wang et al.   Protein & Cell

Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells

(2020) Manon Lernoux et al.   Clinical Epigenetics

xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner

(2020) Keiko Miyamoto et al.   Cancers

HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models

(2020) Trang Thi Thu Nguyen et al.   JOURNAL OF CLINICAL INVESTIGATION

The application of histone deacetylases inhibitors in glioblastoma

(2020) Rui Chen et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight

(2020) Terence C. S. Ho et al.   JOURNAL OF MEDICINAL CHEMISTRY

Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair

(2020) Songwei Huan et al.   Cancer Management and Research

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

(2020) Flávia Alves Verza et al.   Cancers

Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment

(2020) Runzhe Chen et al.   CLINICAL CANCER RESEARCH

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

(2020) Monique B. Nilsson et al.   Science Translational Medicine

SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures

(2020) Camille Tlemsani et al.   Cell Reports

Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

(2019) Megan M. Tu et al.   Science Advances

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Zefei Jiang et al.   LANCET ONCOLOGY

The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells

(2019) Giulia Gobbi et al.   ONCOGENE

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer

(2019) Haitang Yang et al.   Oncogenesis

CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma

(2019) Duo Xu et al.   MOLECULAR CANCER THERAPEUTICS

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)

(2019) Anne Catherine Bretz et al.   Journal for ImmunoTherapy of Cancer

Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma

(2019) Xu et al.   Cancers

Epigenetic modifiers as new immunomodulatory therapies in solid tumours

(2018) S Aspeslagh et al.   ANNALS OF ONCOLOGY

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

(2018) Liqin Wang et al.   CELL

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma

(2018) Jingya Sun et al.   Theranostics

Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition

(2018) Deshui Jia et al.   Cancer Discovery

HDAC1 Substrate Profiling Using Proteomics-Based Substrate Trapping

(2018) Dhanusha A. Nalawansha et al.   ACS Chemical Biology

SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis

(2018) John M. Lamar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer

(2018) Yumeng Wang et al.   Cell Reports

Histone Deacetylase Inhibitors as Anticancer Drugs

(2017) Tomas Eckschlager et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers

(2017) Gilson J Sanchez et al.   NUCLEIC ACIDS RESEARCH

Epigenetic plasticity and the hallmarks of cancer

(2017) William A. Flavahan et al.   SCIENCE

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

(2017) Muhammad Rauzan et al.   PLoS One

Histone Deacetylase Inhibitors in Tumor Immunotherapy

(2017) Li-Ming Zhao et al.   CURRENT MEDICINAL CHEMISTRY

Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells

(2016) Chun-Hao Pan et al.   BMC CANCER

Targeting the cancer epigenome for therapy

(2016) Peter A. Jones et al.   NATURE REVIEWS GENETICS

Correlating chemical sensitivity and basal gene expression reveals mechanism of action

(2015) Matthew G Rees et al.   Nature Chemical Biology

HDAC inhibitors and immunotherapy; a double edged sword?

(2015) Michiel Kroesen et al.   Oncotarget

Regulation of Ferroptotic Cancer Cell Death by GPX4

(2014) Wan Seok Yang et al.   CELL

An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules

(2013) Amrita Basu et al.   CELL

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study

(2013) Wieneke A Buikhuisen et al.   LANCET ONCOLOGY

TCPA: a resource for cancer functional proteomics data

(2013) Jun Li et al.   NATURE METHODS

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma

(2013) Chunzhi Zhang et al.   NEURO-ONCOLOGY

Histone Acetylation-Mediated Regulation of the Hippo Pathway

(2013) Dipanjan Basu et al.   PLoS One

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

(2011) T. Nguyen et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance

(2011) Robert W. Robey et al.   MOLECULAR PHARMACEUTICS

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Nonhistone protein acetylation as cancer therapy targets

(2010) Brahma N Singh et al.   Expert Review of Anticancer Therapy

Histone H3K27ac separates active from poised enhancers and predicts developmental state

(2010) M. P. Creyghton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rational Combinations Using HDAC Inhibitors

(2009) M. Bots et al.   CLINICAL CANCER RESEARCH

The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer

(2009) M. C. Crisanti et al.   MOLECULAR CANCER THERAPEUTICS

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis

(2009) F. Bruzzese et al.   MOLECULAR CANCER THERAPEUTICS

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS